Rein Therapeutics, Inc. reported on September 16, 2025, that the FDA reviewed previous findings regarding its Phase 2 clinical trial for LTI-03, stating no dose-limiting concerns were found, and recommended submitting a Complete Response Letter to address safety issues. The company hopes to submit this CRL shortly and is optimistic it will lead to lifting the clinical hold on the trial.